---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034493"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:29:16.870454+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience issues $150,000 in demand promissory notes to CEO and entity controlled by CFO

## Summary
- $75,000 from CEO Steven Shum ($60,000 on Nov 29, $15,000 on Dec 2, 2022).
- $75,000 from Andax LLC, an entity controlled by CFO Andrea Goren, on Nov 29, 2022.
- Notes are interest-free if paid before Jan 31, 2023; otherwise 10% annual interest from issuance.
- At maturity, principal plus a 10% financing fee and accrued interest are payable.
- Notes callable with 10 days written notice starting 30 days from issuance.

## SEC filing metadata
- accession: 0001493152-22-034493
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315222034493/0001493152-22-034493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315222034493/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034493
- JSON: https://secwatch.observer/filing/0001493152-22-034493.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034493.txt

## Key facts
- Debt Financings
  INVO Fertility, Inc. incurred loan of $150,000 with Steven Shum and entity controlled by Andrea Goren at 10% annual interest.
  - Instrument: loan
  - Principal: $150,000
  - Counterparty: Steven Shum and entity controlled by Andrea Goren
  - Rate: 10% annual interest
  - Event: incurrence
  source text: From November 29, 2022 through December 2, 2022, INVO Bioscience, Inc. (the “Company”) received $150,000 through the issuance of demand promissory notes of which (1) $75,000 was received from our Chief Executive Officer, Steven Shum ($60,000 on November 29, 2022 and $15,000 on December 2, 2022) and (2) $75,000 was received from an entity controlled by our Chief Financial Officer, Andrea Goren (on November 29, 2022). If paid prior to January 31, 2023, the demand promissory notes are interest free until January 31, 2023. For any amount that remains outstanding past January 31, 2023, 10% annual interest would accrue from the date of issuance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315222034493/0001493152-22-034493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.